RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
US$Â 27.64
arrow_downward
-3.41%(-0.98) Siku 1
US$Â 27.64
0.00% (0.00)
bedtimeBaada ya saa
Imefungwa: 22 Jul, 16:00:00 GMT -4 · USD
search
Alama zote
Siku 1
Siku 5
Mwezi 1
Miezi 6
YTD
Mwaka 1
Miaka 5
ISIZIDI
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya RARE...
Fungua
US$Â 28.62
Juu
US$Â 28.86
Chini
US$Â 27.50
Mtaji wa soko
2.72B
Wastani wa kiasi cha mauzo
2.71M
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
US$Â 39.89
Chini kwa wiki 52
US$Â 18.29
EPS
-US$Â 6.10
Beta
0.31
Hisa za wawekezaji
98.49M
Idadi ya wafanyakazi
elfu 1
Fungua
US$Â 28.62
Juu
US$Â 28.86
Chini
US$Â 27.50
Mtaji wa soko
2.72B
Wastani wa kiasi cha mauzo
2.71M
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
US$Â 39.89
Chini kwa wiki 52
US$Â 18.29
EPS
-US$Â 6.10
Beta
0.31
Hisa za wawekezaji
98.49M
Idadi ya wafanyakazi
elfu 1
Habari
Kutoka kwenye vyanzo vya wavuti
Trefis
·
siku 1 iliyopita
Ultragenyx Pharmaceutical Stock Slides 20% With A 9-Day Losing Spree
Trefis
·
siku 1 iliyopita
Ultragenyx Pharmaceutical Stock Extends A 9-Day Losing Streak To A 20% Loss
Wasifu
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Kuhusu Ultragenyx Pharmaceutical Inc
Afisa Mkuu Mtendaji (CEO)Emil Kakkis
Wafanyakazielfu 1.37
Lilianzishwa2010
Makao makuuNovato, California, Marekani
Sekta-
Tovutiultragenyx.com
Maudhui yaliyotayarishwa kwa AI yanaweza kuwa na makosa. Pata maelezo zaidi